Difference between revisions of "Lomustine (CCNU)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA")
m
Line 13: Line 13:
 
*[[Glioblastoma]]
 
*[[Glioblastoma]]
 
*[[Low-grade glioma]]
 
*[[Low-grade glioma]]
 +
*[[Medulloblastoma]]
  
 
==Diseases for which it was used==
 
==Diseases for which it was used==
Line 41: Line 42:
 
[[Category:Glioblastoma medications]]
 
[[Category:Glioblastoma medications]]
 
[[Category:Low-grade glioma medications]]
 
[[Category:Low-grade glioma medications]]
 +
[[Category:Medulloblastoma medications]]
  
 
[[Category:FDA approved in 1976]]
 
[[Category:FDA approved in 1976]]

Revision as of 23:04, 18 November 2018

General information

Class/mechanism: Nitrosourea, alkylates DNA and RNA and may inhibit certain key enzymatic reactions by carbamoylation of amino acids in proteins.[1][2]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Diseases for which it was used

Patient drug information

Also known as

  • Generic names: CCNU, MeCCNU
  • Brand names: CeeNu, Gleostine
    • In 10/2013, Bristol-Myers Squibb discontinued production of their Lomustine brand name, CeeNu.[5] Lomustine is currently supplied as Gleostine by NextSource Biotechnology LLC.[6]

References